

1 Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients

2 Authors

3 Felix Dewald¹, Martin Pirkl¹, Elvin Ahmadov¹, Martha Paluschinski², Joachim Kühn³,
4 Carina Elsner⁴, Bianca Schulte⁵, Maike Schlotz¹, Göksu Oral¹, Jacqueline Knüfer¹,
5 Michael Bernhard⁶, Mark Michael⁶, Maura Luxenburger², Marcel Andrée², Marc Tim
6 Hennies³, Wali Hafezi³, Marlin Maybrit Müller³, Philipp Kümpers⁷, Joachim Risse⁸,
7 Clemens Kill⁸, Randi Katrin Manegold⁸, Ute von Frantzki⁸, Enrico Richter⁵, Dorian
8 Emmert⁵, Werner O. Monzon-Posadas⁹, Ingo Gräff¹⁰, Monika Kogej¹⁰, Antonia
9 Büning⁵, Maximilian Baum⁵, Finn Teipel¹, Babak Mochtarzadeh¹, Martin Wolff¹,
10 Henning Gruell¹, Veronica Di Cristanziano¹, Volker Burst¹¹, Hendrik Streeck⁵, Ulf
11 Dittmer⁴, Stephan Ludwig³, Jörg Timm², Florian Klein^{1,12,13,*}

12 Affiliations

13 ¹Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931
14 Cologne, Germany

15 ²Institute of Virology, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225
16 Düsseldorf, Germany

17
18 ³Institute of Virology, Faculty of Medicine and University Hospital Muenster, University of Muenster,
19 48149 Muenster, Germany

20 ⁴Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45141 Essen, Germany

21 ⁵Institute of Virology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany

22 ⁶Emergency Department, Medical Faculty and University Hospital of Düsseldorf, Heinrich Heine
23 University Düsseldorf, 40225 Düsseldorf, Germany

24
25 ⁷Division of General Internal and Emergency Medicine, Nephrology, Hypertension and Rheumatology,
26 Department of Medicine D, Faculty of Medicine and University Hospital Muenster, University of
27 Muenster, 48149 Muenster, Germany

28 ⁸Center for Emergency Medicine, University Hospital Essen, University Duisburg-Essen, 45141 Essen,
29 Germany

30 ⁹Occupational Medicine Department, University Hospital Bonn, 53127 Bonn, Germany

31 ¹⁰Emergency Department, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany
32

33 ¹¹Department II of Internal Medicine: Nephrology, Rheumatology, Diabetes and General Internal
34 Medicine, Faculty of Medicine and University Hospital Cologne University of Cologne, 50931 Cologne,
35 Germany

36 ¹²German Center for Infection Research (DZIF), Partner site Bonn-Cologne, 50937 Cologne, Germany

37 ¹³Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany

38 * Corresponding author

39

40

41

42

43

44

45

46

47

48

49

50

51

52 **Abstract**

53 Determining SARS-CoV-2 immunity is critical to assess COVID-19 risk and the need
54 for prevention and mitigation strategies. We measured SARS-CoV-2
55 Spike/Nucleocapsid seroprevalence and serum neutralizing activity against Wu01,
56 BA.4/5 and BQ.1.1 in 1,411 individuals who received medical treatment in five
57 emergency departments in North Rhine-Westphalia, Germany. We detected Spike-IgG
58 in 95.6%, Nucleocapsid-IgG in 24.0% and neutralization against Wu01, BA.4/5 and
59 BQ.1.1 in 94.4%, 85.0%, and 73.8% of participants, respectively. Neutralization
60 against BA.4/5 and BQ.1.1 was reduced 5.6- and 23.4-fold compared to Wu01.
61 Accuracy of S-IgG detection for determination of neutralizing activity against BQ.1.1
62 was reduced substantially. Furthermore, we explored previous vaccinations and
63 infections as most important correlates of improved BQ.1.1 neutralization using
64 multivariable and Bayesian network analyses. Given an adherence to COVID-19
65 vaccination recommendations of only 67.7% of all participants, we highlight the need
66 for improvement of vaccine-uptake to reduce the COVID-19 risk in upcoming infection-
67 waves with immune evasive variants.

68

69

70

71

72

73 Introduction

74 Population immunity against SARS-CoV-2 will play a key role in the course of the
75 pandemic and determine morbidity and mortality of COVID-19¹⁻³. To date, 3 years after
76 the emergence of SARS-CoV-2, immune evasion presents the most significant
77 challenge to combat COVID-19⁴⁻⁸.

78 At the beginning of 2022, a rapid surge of infections was detected worldwide and driven
79 by the Omicron variant that exhibited substantial immune evasion properties⁹⁻¹¹.
80 Subsequently, multiple Omicron sub-lineages evolved, including BA.5 that
81 accumulated additional mutations in the Spike protein and became the predominant
82 variant globally in June 2022¹². To that date, BA.5 demonstrated the strongest immune
83 escape from antibodies induced by either SARS-CoV-2 vaccination or infection as well
84 as from therapeutic monoclonal antibodies¹³⁻¹⁷. However, the continuous evolution of
85 the Omicron variant gave rise to further sub-lineages, including BQ.1 and BQ.1.1 with
86 a relative share of all sequenced variants worldwide of 0.1% in August, but 49.7% in
87 November 2022^{18,19}. This increase is likely to be caused by additional immune evasion
88 properties in the BQ.1 and BQ.1.1 subvariants, enabling infections of SARS-CoV-2
89 vaccinated and convalescent individuals. Indeed, early data on neutralization
90 resistance of BQ.1 and BQ.1.1 show that it is mainly driven by a N460K mutation while
91 the R346T and K444T mutations of BQ.1.1 contribute to a lesser extent²⁰⁻²³.
92 Furthermore, in comparison with BA.5, enhanced fusogenicity of BQ.1 and BQ.1.1
93 could be observed^{22,24}.

94 In this multicenter-study, we determined SARS-CoV-2 Spike (S)-IgG levels,
95 Nucleocapsid (NC)-IgG levels and serum neutralization against Wu01, BA.4/5 and

96 BQ.1.1 in 1,411 patients that received medical treatment at emergency departments
97 of five university hospitals in North Rhine-Westphalia, Germany between August and
98 September 2022. We combined IgG levels and neutralization activity with detailed
99 information on medical history and SARS-CoV-2 immune status of the participants.
100 Finally, we conducted multivariable analysis and Bayesian network analysis to provide
101 a better understanding on factors determining quantity and quality of the antibody
102 response to SARS-CoV-2. Our results inform on SARS-CoV-2 immune status and its
103 predictive factors, which helps to assess COVID-19 risk in highly vulnerable groups.

104

105 **Results**

106 **Characteristics of study participants to determine SARS-CoV-2 humoral** 107 **immunity**

108 To determine SARS-CoV-2 point seroprevalence and neutralization activity, we
109 conducted a multi-center cross-sectional seroprevalence study in five emergency
110 departments of university hospitals (maximum care hospitals) in North Rhine-
111 Westphalia, Germany (**Fig. 1a and b**). During the time of sample collection (August
112 and September 2022), 10,191 patients sought medical treatment in the emergency
113 departments. Of those patients, 1,411 (13.9%) were enrolled for study participation.
114 There was no significant difference between age and sex distributions of all emergency
115 department patients and the study participants, indicating representativeness of the
116 study sample for the source population (**Supplementary Fig. 1, Supplementary Fig.**
117 **2**). We collected serum blood samples from all participants and determined S- and NC-

118 IgG reactivity using chemiluminescence immunoassay (CLIA) and enzyme-linked
119 immunosorbent assay (ELISA). Pseudovirus neutralization assays were performed to
120 determine serum neutralizing activity against SARS-CoV-2 Wu01, BA.4/5, and BQ.1.1
121 variants (**Fig. 1a**). Information on epidemiological and clinical data as well as
122 information on COVID-19 vaccination status and previous infections were collected in
123 structured interviews and extracted from medical records. Enrolled participants had a
124 median age of 53 years (range 18-98, IQR: 35-69) with an overall balanced sex
125 distribution (48.5% female; 51.3% male; **Fig. 1, Supplementary Table 1**). 64.2% of
126 the participants reported pre-conditions related most frequently to cardiovascular
127 (52.3%) and neoplastic (24.4%) diseases (**Fig. 1d**). 13.6% of the participants reported
128 drug immunosuppression at the time of sample collection (**Fig. 1e**). 94.4% of the
129 participants reported to have received at least one immunization with an EU-approved
130 vaccine (**Fig. 1f**) and 45.7% reported at least one previous SARS-CoV-2 infection,
131 resulting in 50.8% of the participants exposed to at least 4 previous S-antigen contacts
132 from either vaccination or infection (**Fig. 1g**). Thus, when stratified by age, 67.7% of all
133 participants were vaccinated according to German COVID-19 vaccination
134 recommendations²⁵ (**Fig. 1f**).

135 **High S-IgG sero-prevalence in patients visiting emergency departments in North** 136 **Rhine-Westphalia, Germany**

137 To determine SARS-CoV-2 humoral immunity, we first measured seroprevalence and
138 levels of S-IgG in all participants. S-IgG could be detected in 95.6% of the participants.
139 Of the 4.4% S-IgG-negative participants, 27.9% reported drug immunosuppression at
140 the time of sampling. Of those reporting no drug immunosuppression, 31.8%, 29.5%,

141 6.8%, 22.7%, 6.8% and 2.3% reported 0, 1, 2, 3, 4 or > 4 previous S-antigen contacts,
142 respectively (**Fig. 2a**). Thus, considering German COVID-19 vaccination
143 recommendations²⁵, 86.9% of the sero-negative participants were either
144 immunosuppressed and/or insufficiently vaccinated. Next, we characterized S-IgG
145 levels stratified by sex, age, pre-conditions, drug immunosuppression, and the number
146 of S-antigen contacts (**Fig. 2b**). S-IgG levels were not significantly different between
147 females and males (GeoMean 1,697 versus 1,836 BAU/ml, Mann-Whitney test: $p =$
148 0.663), different age groups (18-30, 31-60, and > 60 years; 2,003, 1,612, and 1,858
149 BAU/ml; Kruskal-Wallis test: $p = 0.357$) and participants with or without pre-conditions
150 (GeoMean 1,884 versus 1,698 BAU/ml; Mann-Whitney test: $p = 0.538$) but lower in
151 participants with drug immunosuppression compared to those without (GeoMean
152 1,042 versus 1,908 BAU/ml, Mann-Whitney test: $p = 0.0005$). Furthermore, S-IgG
153 increased with increasing number of reported S-antigen contacts from 86 to 4,450
154 BAU/ml for 0 to > 4 reported S-antigen contacts (Kruskal-Wallis test: $p < 0.0001$; Dunn's
155 multiple comparisons tests: 0 versus 1, $p > 0.999$; 1 versus 2, $p = 0.029$; 2 versus 3, p
156 $= 0.06$; 3 versus 4, $p < 0.001$; 4 versus > 4, $p = 0.49$). Like the total number of total S-
157 antigen contacts, the number of received vaccinations or previous infections and NC-
158 IgG serostatus affected S-IgG levels significantly (**Supplementary Fig. 3**).

159 **NC-IgG seroprevalence contributes to prediction of S-IgG levels**

160 Next, we determined seroprevalence and levels of NC-IgG in all participants. NC-IgG
161 could be detected in 24.0% of the enrolled participants (**Fig. 2c**). Of all NC-IgG-positive
162 participants, 77.3% and of all NC-IgG-negative participants, 31.9% reported at least
163 one previous SARS-CoV-2 infection, respectively. The fractions of NC-IgG-positive

164 participants were higher in those that reported previous infections (10.0%, 39.0%,
165 61.8% for 0, 1 or 2 previous infections, respectively). Furthermore, NC-IgG values were
166 higher in participants with 2 previous infections compared to those with 1 or no infection
167 (mean S/CO 2.5 and 2.4 for 0 and 1 infection versus 3.3 for 2 infections, Dunn's
168 multiple comparisons test: 0 versus 1, $p = 0.038$; 0 versus 2, $p = 0.029$). In all NC-IgG-
169 positive or -borderline participants with 1 reported infection within the last 6 months (n
170 = 199), mean S/CO decreased from 5.13 to 1.44 during the first 6 months after
171 infection.

172 Given the observed influence of different clinical and serological features on S-IgG
173 levels, we performed multivariable analysis including sex, height, weight, BMI, age,
174 pre-conditions, drug immunosuppression, number of reported vaccinations and
175 infections, time since last vaccination and infection (months) and NC-IgG serostatus in
176 a stepwise regression model (**Fig. 2d**). Features were only added when they
177 significantly improved the model according to a likelihood ratio test. The resulting
178 model (adjusted $R^2 = 0.241$) showed that NC-IgG detection is most predictive for S-
179 IgG levels ($p < 2 \times 10^{-16}$), followed by the number of vaccinations ($p < 2 \times 10^{-16}$), time
180 since infection ($p = 0.008$), time since last vaccination ($p = 0.007$), drug
181 immunosuppression ($p = 0.007$), and number of infections ($p = 0.008$). Sex, weight,
182 BMI, height, pre-conditions, and age were no significant parameters for S-IgG
183 prediction. Bayesian network analysis revealed that NC-IgG serostatus, number of
184 previous infections and received vaccinations directly predicted S-IgG levels while
185 other parameters were only indirectly predictive (**Fig. 2e**).

186 **High S-IgG levels correlate with SARS-CoV-2 neutralizing activity**

187 To determine serum neutralization against Wu01 and BA.4/5 variants, we first
188 determined the fraction of participants that showed detectable serum neutralization
189 indicated by serum $ID_{50s} > 10$. Of all participants, 94.4% and 84.9% showed
190 neutralizing activity against Wu01 and BA.4/5, respectively (**Fig. 3a**). The geometric
191 mean of ID_{50} was significantly lower for neutralizing activity against BA.4/5 than against
192 Wu01 (243 vs. 1,440) which corresponds to a 5.92-fold decrease in serum
193 neutralization (Wilcoxon matched-pairs signed rank test: $p < 0.0001$; **Fig. 3a**). Next,
194 we correlated S-IgG values of all participants with detectable S-IgG against ID_{50} values
195 of all participants with detectable serum neutralization ($n=1,176$) against Wu01 ($r_s =$
196 0.74 , $p < 0.0001$) and BA.4/5 ($r_s = 0.62$, $p < 0.0001$) (**Fig. 3b**). Finally, we computed
197 the fractions of log-tiered serum ID_{50} categories for Wu01 and BA.4/5 stratified by S-
198 IgG levels categorized by log-tiered BAU/ml categories (**Fig. 3c**). No neutralizing
199 activity could be detected against Wu01 and BA.4/5 for S-IgG levels of 10-100 BAU/ml,
200 in 32.4% and 64.7% of the participants, and for S-IgG levels between 100 and 1,000
201 BAU/ml, in 2.7% and 35.6% of the participants, respectively.

202 We conclude that IgG-detection can assess immunity against SARS-CoV-2, however
203 decreased accuracy for the prediction of serum neutralizing activity introduced by
204 immune evasive variants must be considered.

205 **S-IgG levels and S-antigen contacts are most predictive for serum neutralization** 206 **against Wu01 and BA.4/5**

207 To explore predictive features for serum neutralization, we first characterized
208 neutralizing activity against Wu01 and BA.4/5 stratified by sex, age, pre-conditions,
209 drug immunosuppression, number of received vaccinations, number of previous

210 infections, and NC-IgG serostatus (**Fig. 4a**). While serum neutralization was not
211 significantly different between females and males, participants aged 18-30 years had
212 a significantly higher geometric mean of ID₅₀ compared to participants aged 31-60 and
213 > 60, both for neutralization against Wu01 and BA.4/5 (ID₅₀ GeoMean_{Wu01}: 2,306
214 versus 1,212 and 1,405, Dunn's multiple comparisons tests: $p = 0.002$ and $p = 0.029$;
215 ID₅₀ GeoMean_{BA.4/5}: 613 versus 231 and 167; Dunn's multiple comparisons tests: $p <$
216 0.0001 and $p < 0.0001$). Furthermore, serum neutralization was affected by drug
217 immunosuppression at the time of study participation (ID₅₀ GeoMean_{Wu01}: 1,583 versus
218 747; ID₅₀ GeoMean_{BA.4/5}: 267 versus 117; Dunn's multiple comparisons tests: $p =$
219 0.0006 and $p = 0.002$) and the presence of pre-conditions (ID₅₀ GeoMean_{Wu01}: 1,227
220 versus 1,919; ID₅₀ GeoMean_{BA.4/5}: 190 versus 385; Dunn's multiple comparisons tests:
221 $p = 0.004$ and $p = 0.0001$). Serum neutralization against Wu01 and BA.4/5 was
222 significantly higher in vaccinated participants in comparison to unvaccinated (Kruskal-
223 Wallis test: $p < 0.0001$), in participants that reported previous infections compared to
224 those that did not (Kruskal-Wallis test: $p < 0.0001$) and in participants with detectable
225 NC-IgG levels compared to those without (Mann-Whitney test: $p < 0.0001$) (**Fig. 4a**).

226 For serum neutralization against Wu01, multivariable regression (adjusted $R^2 =$
227 0.5955) showed S-IgG levels as most predictive ($p < 2 \times 10^{-16}$), followed by time since
228 infection ($p = 0.012$), pre-conditions ($p = 0.0003$), time since vaccination ($p = 0.004$),
229 number of vaccinations ($p = 0.003$), and number of infections ($p = 0.017$). Bayesian
230 network analysis revealed that S-IgG serostatus, NC-IgG serostatus, number of
231 previous infections and vaccinations, and pre-conditions were directly predictive for
232 serum neutralization against Wu01 (**Fig. 4b**). For serum neutralization against BA.4/5,
233 the model (adjusted $R^2 = 0.5848$) showed S-IgG levels as most predictive ($p < 2 \times 10^{-$

234 ¹⁶), followed by number of previous infections ($p < 2 \times 10^{-16}$), NC-IgG serostatus ($p <$
235 2×10^{-16}), age ($p = 0.0001$), and number of received vaccinations ($p = 0.076$). Bayesian
236 network analysis revealed that S-IgG serostatus, NC-IgG serostatus, age, number of
237 previous infections, and time since infection were directly predictive for serum
238 neutralization against BA.4/5 (**Fig. 4c**).

239 We concluded that SARS-CoV-2 immune response is complex and determined by
240 several factors. However, previous S-antigen contacts, that is, vaccinations and/or
241 infections, substantially contribute to SARS-CoV-2 humoral immunity.

242 **Impaired serum neutralization activity against Omicron sub-lineage BQ.1.1**

243 After completion of sample collection, a rapid spread of the BA.4/5-sublineage BQ.1.1
244 exhibiting three additional mutations in the Spike-protein in comparison to BA.4/5
245 (R346T, K444T, and N460K) could be observed (**Fig. 5a and b**). To determine serum
246 neutralizing activity against BQ.1.1, we draw a proportionate stratified random sub-
247 sample of 423 out of all 1,411 participants (29.9%) to be additionally tested in
248 pseudovirus neutralization assay against BQ.1.1. Strata were defined by sex and 10-
249 years age categories (**Supplementary Fig. 4a**). There were no significant differences
250 in age and sex distributions (**Supplementary Fig. 4b**) as well as in S-IgG levels or
251 neutralizing activity against Wu01 and BA.4/5 (**Supplementary Fig. 5**) between the
252 sub-sample and the entire study population, confirming representativeness of the sub-
253 sample for the entire study sample. While neutralizing activity against Wu01 and
254 BA.4/5 was detectable in 93.9% and 84.9% of the participants, only 73.8% of the
255 studied participants presented activity against the Omicron sub-lineage BQ.1.1.
256 Geometric mean ID₅₀s were 1,302, 231, and 55 (Friedmann test: $p < 0.0001$; Dunn's

257 multiple comparisons tests: $p < 0.0001$, $p < 0.0001$, $p < 0.0001$) for the respective
258 variants. Overall, neutralizing activity against BQ.1.1 was reduced 23.6-fold and 4.2-
259 fold in comparison to neutralizing activity against Wu01 and BA.4/5, respectively (**Fig.**
260 **5c**). The subsequent correlation of S-IgG values of all participants with detectable S-
261 IgG against ID_{50} values of all participants with detectable serum neutralization ($n =$
262 294) against Wu01 ($r_s = 0.64$, $p < 0.0001$), BA.4/5 ($r_s = 0.44$, $p < 0.0001$), and BQ.1.1
263 ($r_s = 0.48$, $p < 0.0001$) revealed rather parallel fit lines and in comparison to Wu01 and
264 a decrease of the intercepts for BA.4/5 and BQ.1.1, respectively (**Fig. 5d**, left panel).
265 For S-IgG levels of 10-100 BAU/ml in 85.7%, and for S-IgG levels of 100-1,000 BAU/ml
266 in 55.6% of the participants, no serum neutralization against BQ.1.1 could be detected
267 (**Fig. 5d**, right panel). Spearman correlations between ID_{50} values of Wu01 versus
268 BA.4/5 ($r_s = 0.75$), Wu01 versus BQ.1.1 ($r_s = 0.67$), and BA.4/5 versus BQ.1.1 ($r_s =$
269 0.78) revealed a stronger correlation between Wu01 and BA.4/5 serum neutralization
270 than between Wu01 and BQ.1.1 serum neutralization, reflecting the improved immune
271 escape of BQ.1.1 (**Fig. 5e**).

272 Finally, we performed multivariable regression and Bayesian network analysis as
273 described above to further explore and predict serum neutralization against BQ.1.1.
274 The resulting model (adjusted $R^2 = 0.477$) showed S-IgG levels as most predictive (p
275 $= 2 \times 10^{-16}$), followed by number of previous infections ($p = 6.47 \times 10^{-5}$) and NC-IgG
276 serostatus ($p = 2.7 \times 10^{-6}$), age ($p = 0.001$), and BMI ($p = 0.007$), while all other features
277 were not statistically significant. Bayesian network analysis revealed that S-IgG, NC-
278 IgG, time since infection, and age were directly predictive for serum neutralization
279 against BQ.1.1 (**Fig. 5f**).

280 We concluded that serum neutralization of the participants is impaired against BQ.1.1.
281 Furthermore, previous S-antigen contacts are most predictive for serum neutralizing
282 activity against BQ.1.1, as observed for Wu01 and BA.4/5.

283

284 **Discussion**

285 Given the substantial immune escape of SARS-CoV-2 variants, for the assessment of
286 population immunity, completing S-IgG seroprevalence with serum neutralizing activity
287 is essential^{26,27}. This can help to assess the COVID-19 risk and inform on public health
288 measures, such as vaccination strategies for Omicron-adapted vaccines, mask
289 requirements, and further concepts of prevention. At the time of sample collection,
290 there was an urgent need for assessing the COVID-19 risk of vulnerable groups in
291 autumn and winter 2022/2023 in Germany. For that reason, we conducted a cross-
292 sectional point-seroprevalence study in patients that received medical treatment in
293 emergency departments because we expected a high prevalence of pre-conditions
294 and risk factors for severe courses of COVID-19 in those patients.

295 Our results demonstrate a high fraction of participants (95%) with detectable S-IgG but
296 only moderate adherence to current recommendations on COVID-19 vaccinations
297 (67%)²⁵. The fraction of participants that reported previous infections (45%) was high
298 and our results show that previous infections significantly contribute to neutralizing
299 activity against SARS-CoV-2, which is in line with other studies^{8,28–30}. Importantly, no
300 data on the clinical course of the infections were available in our study. Accordingly,
301 we do not conclude that infections rather than vaccinations represent a possible

302 strategy in the future for boosting immunity in risk groups. Furthermore, in contrast to
303 vaccinations, timing and outcome of infections are not predictable.

304 Most strikingly, we showed a 23-fold decrease in serum neutralizing activity against
305 BQ.1.1 in comparison to Wu01. This is in line with to date limited data on BQ.1.1
306 immune escape and highlights BQ.1.1 as one of the variants with the highest extent of
307 immune escape that have been observed so far^{13–17,22,23,31,32}. We could not
308 differentiate the immune escape to infection-induced antibody response and/or
309 antibodies induced by mono- or bivalent vaccinations. However, substantial
310 neutralization resistance of BQ.1.1 after BA.5 infections was shown previously²² and
311 bivalent vaccination was shown to elicit lower neutralizing activity against BQ.1.1 than
312 against BA.5²¹.

313 As shown in our multivariable regression model and Bayesian network analysis, S-IgG
314 levels were most predictive for neutralization activity against BQ.1.1. However, we find
315 it important to emphasize that 59.6% of the individuals with detectable S-IgG < 1000
316 BAU/ml showed no detectable neutralizing activity against BQ.1.1, highlighting the
317 decreased accuracy of S-IgG detection for assessing neutralization in individuals with
318 low S-IgG titers. This information is relevant for clinical routine testing of S-IgG and
319 needs to be considered when assessing COVID-19 risk in patients.

320 To our best knowledge, this study is one of the largest that assesses immune evasion
321 of BA.4/5 and BQ.1.1 in a real-life setting. Furthermore, the comprehensiveness of
322 data on medical history, vaccinations, and previous infections of the participants
323 contribute to a reliable assessment of humoral immunity of vulnerable persons before
324 the worldwide predominance of BQ.1.1. However, our study population is not a

325 representative sample of the general population and by that, external validity of S-IgG
326 seroprevalence is limited. Nevertheless, we expect that the observed impaired serum
327 neutralization against BQ.1.1 can be generalized, as it was controlled for several
328 features including age, pre-conditions, drug immunosuppression and number of
329 previous S-antigen contacts.

330 In summary, we determined a high S-IgG seroprevalence, only a moderate compliance
331 with vaccination recommendations and subsequently a broad range of serum
332 neutralizing activity against BQ.1.1. By that, the observed substantial fraction of
333 persons without detectable neutralizing activity mirrors the consequences of the
334 interplay between immune escape and non-compliance with vaccination
335 recommendations. We conclude that improvement of vaccine-uptake for all eligible
336 individuals is critical, predictable, and feasible for reducing the COVID-19 risk in
337 upcoming waves of BQ.1.1 infections.

338

339 **Methods**

340 **Ethical considerations**

341 All samples and data were obtained under protocols approved by the ethics
342 committees of the Medical Faculty of the University of Cologne (22_1262), of the
343 Medical Faculty of the University of Bonn (314/22), of the Medical Faculty of the
344 University of Düsseldorf (2022-2072), of the Medical Faculty of the University of Essen
345 (22-10838-BO), and of the Medical Faculty of the University of Münster (2022-490-b-

346 S). All participants provided written informed consent. This study was registered as
347 clinical trial (DRKS00029414).

348 **Study design**

349 Recruitment of participants and sample collection was conducted at five study sites in
350 North Rhine-Westphalia, Germany (University Hospital of Cologne, University Hospital
351 of Düsseldorf, University Hospital of Essen, University Hospital of Bonn, and University
352 Hospital of Münster). Participation was offered to patients receiving medical treatment
353 in emergency departments at one of the five study sites between August 8, 2022 and
354 September 19, 2022. The study personnel recruited 1,411 participants in cooperation
355 with the emergency department personnel. Patients were required to meet the
356 following eligibility criteria in order to be enrolled as participants: i) only individuals aged
357 ≥ 18 years were eligible, ii) participants had to be patients at the emergency department
358 at one of the five study sites, iii) patients had to be able to consent to participate, iv)
359 the ability to consent was furthermore checked by the study personnel with a special
360 focus on the medication, pain and the exceptional emotional situation of the patients,
361 and v) according to the assessment of the study personnel, participation in the study
362 should not be a significant additional burden for the patients. After verification of
363 eligibility criteria and obtaining written informed consent by the study physicians, during
364 blood collection, which was part of the standard medical treatment at the emergency
365 departments, up to additional 20 mL of blood was drawn from the participants to be
366 analyzed in this study. Information on epidemiological data (age, sex, nationality, place
367 of residence) and clinical data (body-length and weight, pre-existing conditions,
368 immunosuppressive medication) as well as information on COVID-19 vaccination

369 status (number of shots received, received vaccine type, date of vaccination), and past
370 infections with SARS-CoV-2 (date of positive RT-qPCRs and/or rapid antigen detection
371 tests) was verbally requested by the study personnel or extracted from the medical
372 records of the participants. Samples and data collected at one study site were
373 pseudonymized at that site and analyzed centrally at the study site in Cologne. In
374 addition, serum samples obtained at each study site were analyzed at that site for
375 assessing assay validity as described further in Methods Details.

376 **Processing of serum samples**

377 Samples were transported at 4°C, processed within 48 hours after collection by
378 centrifugation and stored at -80°C till use.

379 **Serological assays**

380 Anti-SARS-CoV-2 antibodies were detected using commercial assays that use either
381 SARS-CoV-2 Spike protein or SARS-CoV-2 Nucleocapsid antigens. All assays were
382 used as per manufacturer's recommendations.

383 S-IgG were measured using DiaSorin's LIAISON® SARS-CoV-2 TrimericS
384 chemiluminescence immunoassay as described previously³³ with the following cut-off
385 values: negative < 33.8 BAU/ml and positive ≥ 33.8 BAU/ml. Positive percent
386 agreement (PPA) and negative percent agreement (NPA) with i) Anti-SARS-CoV-2
387 QuantiVac IgG BAU (Euroimmun) (n = 502, measured at the study site in Düsseldorf)
388 were 99.78% and 83.33%, with ii) DiaSorin's LIAISON® SARS-CoV-2 TrimericS
389 chemiluminescence immunoassay (n = 185, measured at the study site in Essen) were
390 100% and 100%, with iii) Abbott's anti-SARS-CoV-2 IgG Quant II chemiluminescence

391 microparticle assay (Alinity i) (n = 133, measured at the study site in Bonn) were 100%
392 and 66.66% (n = 3), and with iv) Abbott's anti-SARS-CoV-2 IgG Quant II
393 chemiluminescence microparticle assay (Alinity i) (n = 208, measured at the study site
394 in Münster) were 99.5% and 100%. For graphical representation and statistical
395 evaluation of serum samples, in Figures 2, 3, 5, Figure S5, samples that did not
396 achieve IgG levels ≥ 33.8 BAU/ml were imputed to 4.81 BAU/ml (lower limit of
397 quantification).

398 NC-IgG were measured using the Euroimmun anti-SARS-CoV-2-NCP-ELISA. Serum
399 samples were tested on the automated system Euroimmun Analyzer I according to
400 manufacturer's recommendations. S/CO values were interpreted as positive (S/CO
401 ≥ 1.1), borderline (S/CO $\geq 0.8 - < 1.1$), and negative (S/CO < 0.8). PPA and NPA with
402 i) Abbott's Architect SARS-CoV-2 IgG assay (n = 502, measured at the study site in
403 Düsseldorf) were 97.6% and 94.85%, with ii) Abbott's Architect SARS-CoV-2 IgG
404 assay (n = 185, measured at the study site in Essen) were 100% and 95.95%, with iii)
405 Roche's Elecsys®-Assay (n = 133, measured at the study site in Bonn) were 56.86%
406 and 100%, and with iv) Abbott's Architect SARS-CoV-2 IgG (n = 208, measured at the
407 study site in Münster) were 83.05% and 98.92%.

408 **Cell lines**

409 HEK293T cells and 293T-ACE2 cells were maintained in DMEM (Gibco) containing
410 10% FBS, 1% Penicillin-Streptomycin, 1mM L-Glutamine and 1mM Sodium pyruvate.
411 Cells were grown in T75 flasks (Sarstedt) at 37°C and 5% CO₂.

412 **Cloning of SARS-CoV-2 Omicron BA.4/5 and BQ.1.1 spike constructs**

413 Cloning of Wu01- and BA.4/5 spike protein expression plasmids was previously
414 described^{13,34}. Compared with the Wu01 strain spike protein amino acid sequence, for
415 the Omicron BA.4/5 strain, the following changes were included in the plasmid: T19I,
416 Δ 24-26, A27S, D69-70 G142D, V213G, G339D, S371F, S373P, S375F, T376A,
417 D405N, R408S, K417N, N440K, L452R S477N, T478K, E484A, F486V Q498R,
418 N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, and N969K
419 mutations. For the BQ.1.1 spike protein expression plasmid, a gene fragment (Thermo
420 Fisher) encompassing the additional R346T, K444T, and N460K mutations was cloned
421 into the BA.4/5 spike protein expression plasmid using the NEB HiFi DNA Assembly
422 Kit (New England Biolabs). All spike protein expression plasmids incorporate a C-
423 terminal deletion of 21 cytoplasmic amino acids that results in increased pseudovirus
424 titers. Sanger sequencing was used for verification of the spike sequence.

425 **Pseudovirus neutralization assays**

426 For pseudovirus particle production, HEK293T cells were co-transfected with plasmids
427 encoding for the SARS-CoV-2 spike protein, HIV-1 Tat, HIV-1 Gag/Pol, HIV-1 Rev,
428 and luciferase followed by an internal ribosome entry site (IRES) and ZsGreen³⁵.
429 FuGENE 6 Transfection Reagent (Promega) was used for transfection. Virus culture
430 medium was harvested 48-72h after transfection and stored at -80°C. Harvested virus
431 was titrated. To this end, 293T-ACE2 cells³⁵ were infected and incubated 48 h at 37°C
432 and 5% CO₂ prior to luciferase activity assessment. Activity was determined using a
433 microplate reader (Berthold) after addition of luciferin/lysis buffer (10 mM MgCl₂,
434 0.3 mM ATP, 0.5 mM Coenzyme A, 17 mM IGE PAL (all Sigma-Aldrich), and 1 mM D-
435 Luciferin (GoldBio) in Tris-HCL). After heat inactivation (56°C at 45 min), serum

436 samples were serially diluted (1:3), starting with a 1:10 dilution. Before the addition of
437 293T-ACE2 cells, dilutions of serum samples were co-incubated with pseudovirus
438 supernatants for 1h at 37°C. All samples were tested in single dilution series. Using
439 the reagents described above, luciferase activity was determined after 48h incubation
440 at 37°C and 5% CO₂. To quantify neutralization activity, after subtraction of background
441 RLUs of non-infected cells, the 50% inhibitory dose (ID₅₀) was determined. ID₅₀ was
442 defined as the serum dilution which resulted in a 50% reduction in RLUs in comparison
443 with the untreated virus control cells. GraphPad Prism 9 was used for calculation of
444 ID₅₀ which was plotted as dose response curve. A SARS-CoV-2 neutralizing
445 monoclonal antibody was used as run control. Assay specificity was described
446 before³⁶. Average inter-assay coefficient was determined as 18.09%, by testing 1,546
447 serum samples in duplicates on different plates and different days. For graphical
448 representation and statistical evaluation of serum samples in Figures 3, 4, 5 and Figure
449 S5 samples that did not achieve 50% inhibition at the lowest tested dilution of 10 (lower
450 limit of quantification, LLOQ) were imputed to ID₅₀ = 4 and serum samples with ID₅₀s
451 >21,870 (upper limit of quantification) were imputed to ID₅₀ = 21,871.

452 **SARS-CoV-2 variant frequencies**

453 SARS-CoV-2 variant proportions were extrapolated from bi-weekly Our world in Data
454 dashboard (<http://ourworldindata.org>, accessed on November 25, 2022) and weekly
455 reports of the Robert Koch Institute.

456 **Quantification and statistical analysis**

457 We used a stepwise forward regression to select features in a linear regression model.
458 We distinguished between continuous features (age, height, weight, BMI, S-IgG,
459 serum ID₅₀ Wu01, serum ID₅₀ BA.4/5, serum ID₅₀ BQ.1.1, number of previous
460 infections, number of vaccinations, time since infection and time since vaccination) and
461 categorical features (sex, preconditions, NC-IgG and drug immunosuppression)
462 (**Figures 2d, 4b, 4c, 5f**). We removed all patient samples with no data for at least one
463 feature, either missing or not specified. Our final data set had a size of 1,209, 1,209,
464 1,207 and 352 for S-IgG, serum ID₅₀ Wu01, serum ID₅₀ BA.4/5, and serum ID₅₀ BQ.1.1,
465 respectively. We transformed the features with a skewed distribution (S-IgG, Serum
466 ID₅₀, and time since infection) by adding 1 and taking the log with base 10. We used
467 stepwise forward regression for feature selection. We started with the base model, only
468 including the intercept and iteratively added the feature that increased the model fit the
469 most. We tested the increase of the model fit with a likelihood-ratio test (R package
470 lmtest). We did not include any Serum ID₅₀ features as predictors. We standardized
471 the continuous features in our final model with mean zero and standard deviation 1 to
472 allow for the comparison of the coefficients. For the next analysis, the larger data sets
473 shrunk to 1,181 participants, because we included all features into one model, which
474 led to more missing data in several participants. We created 1,000 different datasets
475 by sampling 1,181 respectively 352 patients with replacement from the original
476 participant dataset. We used the score-based hill-climbing algorithm (R package
477 bnlearn) to compute a Bayesian network for each dataset (**Figures 2e, 4b, 4c, 5f**). We
478 restricted the response from having outgoing edges to preserve the directionality of the
479 regression. We computed the edge fractions from the 1,000 Bayesian networks and

480 defined a consensus network by including edges with a fraction of 0.5, i.e., 500 or more
481 appearances.

482 Testing for statistical significance of differences in sex distribution between the study
483 population and the study sample was performed with the two-sided Fisher's exact test.
484 Testing for statistical significance of differences in S-IgG levels, NC-IgG S/CO values
485 or serum neutralization titers against Wu01, BA.4/5 and BQ.1.1 was performed with
486 the two-sided Kruskal-Wallis test, Friedman test, Mann-Whitney U test or Wilcoxon
487 matched pairs signed rank test, using Prism 9.0 (GraphPad). Dunn's multiple
488 comparisons tests were performed as post-hoc tests (GraphPad). Spearman's rank
489 correlation coefficients (R_s) were determined using Prism 9.0 (GraphPad). Non-linear
490 regression (robust regression) was calculated using Prism 9.0 (GraphPad). Statistical
491 significance was defined as $p < 0.05$. Details are additionally provided in the
492 Figure legends.

493

494 **Additional software**

495 Maps of Germany and North Rhine-Westphalia were designed with the iMapU tool
496 provided by iExcelU.

497

498 **Data availability**

499 Raw data reported in this paper will be shared by the lead contact upon reasonable
500 request.

501 **Code availability**

502 All original code has been deposited online³⁷ and is publicly available as of the date
503 of publication.

504

505 **References**

- 506 1. Lopez Bernal, J. *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2
507 (Delta) Variant. *N Engl J Med* **385**, 585–594 (2021).
- 508 2. Tseng, H. F. *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron
509 and Delta variants. *Nature Medicine* **28**, 1063–1071 (2022).
- 510 3. Nyberg, T. *et al.* Comparative analysis of the risks of hospitalisation and death
511 associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants
512 in England: a cohort study. *The Lancet* **399**, 1303–1312 (2022).
- 513 4. Tran, T. N. A. *et al.* SARS-CoV-2 Attack Rate and Population Immunity in
514 Southern New England, March 2020 to May 2021. *JAMA Netw Open* **5**,
515 e2214171–e2214171 (2022).
- 516 5. Aziz, N. A. *et al.* Seroprevalence and correlates of SARS-CoV-2 neutralizing
517 antibodies from a population-based study in Bonn, Germany. *Nature*
518 *Communications* **12**, 1–10 (2021).
- 519 6. Stringhini, S. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in
520 Geneva, Switzerland (SEROCoV-POP): a population-based study. *The Lancet*
521 **396**, 313–319 (2020).
- 522 7. Goldberg, Y. *et al.* Protection and Waning of Natural and Hybrid Immunity to
523 SARS-CoV-2. *New England Journal of Medicine* **386**, 2201–2212 (2022).
- 524 8. Suryawanshi, R. & Ott, M. SARS-CoV-2 hybrid immunity: silver bullet or silver
525 lining? *Nature Reviews Immunology* **22**, 591–592 (2022).
- 526 9. Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in
527 the COVID-19 pandemic. *Lancet* **6736**, 19–21 (2021).
- 528 10. Brandal, L. T. *et al.* Outbreak caused by the SARS-CoV-2 Omicron variant in
529 Norway, November to December 2021. *Eurosurveillance* **26**, 1–5 (2021).
- 530 11. Pulliam, J. R. C. *et al.* Increased risk of SARS-CoV-2 reinfection associated with
531 emergence of Omicron in South Africa. *Science* (1979) **376**, (2022).

- 532 12. Tegally, H. *et al.* Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5
533 in South Africa. *Nature Medicine* 2022 28:9 **28**, 1785–1790 (2022).
- 534 13. Gruell, H. *et al.* SARS-CoV-2 Omicron sublineages exhibit distinct antibody
535 escape patterns. *Cell Host Microbe* **30**, 1231-1241.e6 (2022).
- 536 14. Cao, Y. *et al.* BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron
537 infection. *Nature* 2022 608:7923 **608**, 593–602 (2022).
- 538 15. Tuekprakhon, A. *et al.* Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5
539 from vaccine and BA.1 serum. *Cell* **185**, 2422-2433.e13 (2022).
- 540 16. Khan, K. *et al.* Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1
541 infection. *Nature Communications* 2022 13:1 **13**, 1–7 (2022).
- 542 17. Hachmann, N. P. *et al.* Neutralization Escape by SARS-CoV-2 Omicron
543 Subvariants BA.2.12.1, BA.4, and BA.5. *New England Journal of Medicine* **387**,
544 86–88 (2022).
- 545 18. Mathieu, E. *et al.* Coronavirus Pandemic (COVID-19). (2020).
- 546 19. TAG-VE statement on Omicron sublineages BQ.1 and XBB.
547 [https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-omicron-](https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-omicron-sublineages-bq.1-and-xbb)
548 [sublineages-bq.1-and-xbb.](https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-omicron-sublineages-bq.1-and-xbb)
- 549 20. Arora, P. *et al.* Omicron sublineage BQ.1.1 resistance to monoclonal antibodies.
550 *Lancet Infect Dis* **0**, (2022).
- 551 21. Zou, J. *et al.* Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2,
552 BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine.
553 doi:10.1101/2022.11.17.516898.
- 554 22. Qu, P. *et al.* Enhanced Neutralization Resistance of SARS-CoV-2 Omicron
555 Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. *Cell Host Microbe*
556 (2022) doi:10.1016/J.CHOM.2022.11.012.
- 557 23. Wang, Q. *et al.* Alarming antibody evasion properties of rising SARS-CoV-2 BQ
558 and XBB subvariants. *Cell* (2022) doi:10.1016/J.CELL.2022.12.018.
- 559 24. Ito, J. *et al.* Convergent evolution of the SARS-CoV-2 Omicron subvariants
560 leading to the emergence of BQ.1.1 variant. *bioRxiv* **11**, 2022.12.05.519085
561 (2022).
- 562 25. Matysiak-Klose, D. *et al.* Empfehlung und wissenschaftliche Begründung der
563 STIKO zur Grundimmunisierung von Personen im Alter von 12 – 17 Jahren mit
564 dem COVID-19-Impfstoff Nuvaxovid von Novavax. *Epid Bull* 52–56 (2022).
- 565 26. Ng, D. L. *et al.* SARS-CoV-2 seroprevalence and neutralizing activity in donor
566 and patient blood. *Nature Communications* 2020 11:1 **11**, 1–7 (2020).
- 567 27. Crawford, K. H. D. *et al.* Protocol and Reagents for Pseudotyping Lentiviral
568 Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses*
569 2020, Vol. 12, Page 513 **12**, 513 (2020).
- 570 28. Ntziora, F. *et al.* Protection of vaccination versus hybrid immunity against
571 infection with COVID-19 Omicron variants among Health-Care Workers. *Vaccine*
572 **40**, (2022).

- 573 29. Goldberg, Y. *et al.* Protection and Waning of Natural and Hybrid Immunity to
574 SARS-CoV-2. *New England Journal of Medicine* **386**, 2201–2212 (2022).
- 575 30. Gazit, S. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
576 2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections
577 versus Breakthrough Infections: A Retrospective Cohort Study. *Clinical*
578 *Infectious Diseases* **75**, e545–e551 (2022).
- 579 31. Gruell, H. *et al.* Antibody-mediated neutralization of SARS-CoV-2. *Immunity* **55**,
580 925–944 (2022).
- 581 32. Cao, Y. *et al.* Imprinted SARS-CoV-2 humoral immunity induces convergent
582 Omicron RBD evolution. *bioRxiv* 2022.09.15.507787 (2022)
583 doi:10.1101/2022.09.15.507787.
- 584 33. Affeldt, P. *et al.* Immune Response to Third and Fourth COVID-19 Vaccination
585 in Hemodialysis Patients and Kidney Transplant Recipients. *Viruses* 2022, Vol.
586 14, Page 2646 **14**, 2646 (2022).
- 587 34. Vanshylla, K. *et al.* Discovery of ultrapotent broadly neutralizing antibodies from
588 SARS-CoV-2 elite neutralizers. *Cell Host Microbe* **30**, 69-82.e10 (2022).
- 589 35. Crawford, K. H. D. *et al.* Protocol and Reagents for Pseudotyping Lentiviral
590 Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12**,
591 (2020).
- 592 36. Vanshylla, K. *et al.* Kinetics and correlates of the neutralizing antibody response
593 to SARS-CoV-2 infection in humans. *Cell Host Microbe* **29**, 917-929.e4 (2021).
- 594 37. Pirkl, M. Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated
595 patients. Preprint at <https://doi.org/https://10.5281/zenodo.7466593> (2022).
596

597

598 **Acknowledgements**

599 We are grateful to all study participants for their dedication to our research. We thank
600 all members of all involved institutes. In particular, we thank Andrea Klöckner, Christian
601 Overath, Anna Lucia Petrucci, Flaurant Ramadani, Claudia Reddig, Jasmin Lange, and
602 Monika Eschbach-Bludau for processing of serum samples and sample logistics. We
603 thank Kanika Vanshylla for the establishing of the pseudovirus neutralization assay.
604 We thank Thorsten Noack-Schönborn for providing data on emergency department
605 patient characteristics. We thank Carsten Tschirner (IExcelU) for supporting data

606 visualization and all laboratories providing SARS-CoV-2 sequencing information to
607 GISAID and subsequently Our world in Data for facilitating variant distribution
608 analyses.

609

610 **Author contributions**

611 Conceptualization, F.D., F.K., J.T., S.L., H.S., C.E., M.P., B.S., U.D.; J.Kü.;
612 methodology, F.D., M.P., F.K.; investigation, F.D., M.P., F.K., E.A. B.M., V.D.C, V.B.,
613 H.G., F.T., M.B., M.M., M.L., M.A., M.T.H., W.H., M.M.M., P.K., J.Kü., M.S., G.O., J.K.,
614 C.E., C.K., D.E., I.G., M.K., W.O.M.-P., J.R., A.B., M.B., R.K.M., M.W., U.V.F., E.R.;
615 resources, F.K., J.T., H.S. U.D., S.L.; formal analysis, F.D., M.P., and F.K.;
616 visualization, F.D.; writing - original draft, F.D., M.P., and F.K.; writing - review &
617 editing, all authors; supervision, F.K.; funding acquisition, F.K., J.T., H.S. U.D., and
618 S.L.

619

620 **Declaration of interest**

621 The authors declare no competing interest.

622

623 **Additional Information**

624 Supplementary Information is available for this paper.

625 Correspondence should be addressed to florian.klein@uk-koeln.de.

626 Funding was provided by the ministry for work, health, and social affairs of the state
627 of North Rhine-Westphalia (CPS-1-1F).

628

629

630 **Figure legends for main text figures**

631 **Fig. 1: Characteristics of study participants to determine SARS-CoV-2 humoral** 632 **immunity**

633 (a) Illustration depicting number of study participants recruited in emergency
634 departments, study timeline and experimental procedures.

635 (b) Illustration depicting the locations of the 5 study sites. Maps of Germany and North
636 Rhine-Westphalia were designed with the iMapU tool provided by iExcelU.

637 (c) Distribution of age and sex of the participants.

638 (d) Pie chart depicting presence of pre-conditions. Bar chart illustrating the distribution
639 of pre-conditions stratified by organ-system.

640 (e) Pie chart depicting presence of drug immunosuppression as reported by the
641 participants at the time of sample collection.

642 (f) Pie chart illustrating vaccination status of the participants. Bar chart depicting
643 reported vaccination scheme stratified by number of received shots. Compliance with
644 vaccination recommendations according to age is indicated by corresponding colors.

645 (g) Bar charts illustrating reported previous infections and total Spike antigen contacts
646 consisting of vaccinations and infections.

647 **Fig. 2: High S-IgG sero-prevalence and factors to predict S-IgG levels**

648 (a) Pie charts illustrating SARS-CoV-2 S-IgG prevalence and presence of drug
649 immunosuppression of Spike negative participants. Bar chart indicating reported
650 number of antigen contacts of participants with no detectable S-IgG and drug
651 immunosuppression.

652 (b) Dot plots depicting S-IgG BAU/ml values, subdivided based on sex, age, pre-
653 conditions, drug immunosuppression, and number of S-antigen contacts. Dotted lines
654 represent the limit of detection (33.8 BAU/ml). Geometric means are indicated by
655 horizontal red lines and listed in each plot over total fractions of participants with
656 detectable S-IgG. Mann-Whitney tests, Kruskal-Wallis-tests and Dunn's multiple
657 comparisons tests were performed for statistical analyses. Ns, *, **, ***, and ****
658 represent p-values ≥ 0.05 , < 0.05 , ≤ 0.01 , ≤ 0.001 , and ≤ 0.0001 , respectively.

659 (c) Left pie charts illustrate NC-IgG prevalence and fractions of participants reporting
660 any or reporting no previous infections in NC-IgG positive and negative participants,
661 respectively. Right pie charts depict NC-IgG prevalence stratified by number of
662 reported previous infections. Dot plot illustrates NC-IgG values (S/CO) stratified by
663 number of reported infections. Dotted lines represent cut-off to negative and borderline
664 (0.8 and 1.1 S/CO). Means are indicated by horizontal red lines. Kruskal-Wallis-test
665 and Dunn's multiple comparisons tests were performed for statistical analyses. * and
666 ns represent p-values < 0.05 and ≥ 0.05 , respectively. NC-IgG S/CO dynamic after

667 infection is illustrated stratified by months after infection. Only data of individuals that
668 reported one previous infection are shown. Individual values, mean S/CO and 95%
669 confidence interval are depicted by black dots, blue line, or grey area, respectively.

670 (d) Stepwise forward regression model for predicting S-IgG (BAU/ml) using continuous
671 features (age, height, weight, body mass index (BMI), number of infections, number of
672 vaccinations, time since infection, and time since vaccination) and categorical features
673 (sex, pre-conditions, NC-IgG, and immunosuppression). Features with $p < 0.05$ in the
674 multivariable regression model are highlighted in red.

675 (e) Bayesian network of the features predicting S-IgG. The graph connects the
676 features, which are predictive of each other with S-IgG as sink. Features with $p < 0.05$
677 in the multivariable regression model (D) are highlighted in red.

678 **Fig. 3: High S-IgG levels correlate with SARS-CoV-2 neutralizing activity**

679 (a) Left: Pie charts illustrating SARS-CoV-2 serum neutralization prevalence (limit of
680 detection $ID_{50} = 10$). Right: Dot plot depicting serum ID_{50} for Wu01 and BA.4/5 variants.
681 Dotted lines represent the limit of detection ($ID_{50} = 10$). Geometric means are indicated
682 by horizontal red lines and listed for both variants over total fractions of participants
683 with detectable serum neutralization. Arrow indicates x-fold decrease of serum
684 neutralization. Two-sided Wilcoxon matched pairs signed rank test was performed for
685 statistical analyses. **** represent a p -value < 0.05 .

686 (b) Spearman correlation of S-IgG (BAU/ml) against serum neutralization (ID_{50}) of
687 Wu01 and BA.4/5 variants indicated by respective colors. Red and blue lines indicate
688 fit lines computed with robust regression.

689 (c) Serum neutralization (ID_{50}) is categorized by indicated color and stratified by S-IgG
690 (BAU/ml) for Wu01 und BA.4/5 variants. Dotted lines represent 50% of all participants
691 in each stratum. N of each stratum is indicated on top of the graphs.

692 **Fig. 4: S-IgG levels and S-antigen contacts are most predictive for serum**
693 **neutralization against Wu01 and BA.4/5**

694 (a) Dot plots depicting serum neutralization ID_{50} values for Wu01 (blue) and BA.4/5
695 (red), subdivided based on sex, age, pre-conditions, drug immunosuppression, pre-
696 conditions, number of vaccinations, number of infections, and NC-IgG detection.
697 Dotted lines represent limit of detection ($ID_{50} = 10$). Geometric means are indicated by
698 horizontal red lines and listed in each plot over total fractions of participants with
699 detectable serum neutralization. Two-sided Kruskal-Wallis-tests, Dunn's multiple
700 comparisons tests and Mann-Whitney tests were performed for statistical analyses.
701 Ns, *, **, ***, and **** represent p-values ≥ 0.05 , < 0.05 , ≤ 0.01 , ≤ 0.001 , and ≤ 0.0001 ,
702 respectively.

703 (b) Stepwise forward regression models for predicting serum neutralization (ID_{50}) using
704 continuous features (age, height, weight, body mass index (BMI), number of infections,
705 number of vaccinations, time since infection, time since vaccination, S-IgG) and
706 categorical features (sex, pre-conditions, NC-IgG and immunosuppression). Features
707 with $p < 0.05$ in the multivariable regression model are highlighted in green.

708 (c) Bayesian networks of the features predicting serum neutralization (ID_{50}). The graph
709 connects the features, which are predictive of each other with Serum neutralization as

710 sink. Features with $p < 0.05$ in the multivariable regression model (B) are highlighted
711 in green.

712 **Fig. 5: Impaired serum neutralization activity against Omicron sub-lineage**
713 **BQ.1.1**

714 (a) Spike amino acid changes in BQ.1.1 relative to BA.4/5 and Wu01.

715 (b) Variant proportions in United Kingdom, Spain, France, and Germany extrapolated
716 from bi-weekly Our world in Data dashboard and weekly reports of the Robert Koch
717 institute (accessed on November 25, 2022). NTD, N-terminal domain; RBD, receptor-
718 binding domain; S, Spike.

719 (c) Dot plot depicting serum neutralization ID_{50} values for Wu01 (blue), BA.4/5 (red),
720 and BQ.1.1 (yellow). Dotted lines represent the limit of detection ($ID_{50} = 10$). Geometric
721 means are indicated by horizontal red lines and listed in each plot over total fractions
722 of participants with detectable serum neutralization. Arrows indicates x-fold decrease
723 of serum neutralization. Two-sided Friedman test and Dunn's multiple comparison
724 tests were performed for statistical analyses. Asterisks represent p -values < 0.05 .

725 (d) Left: Spearman correlation of Spike IgG (BAU/ml) against serum neutralization
726 (ID_{50}) of Wu01, BA.4/5 and BQ.1.1 variants indicated by respective colors. Red, blue
727 and yellow lines indicate fit lines computed with robust regression. Right: Serum
728 neutralization (ID_{50}) is categorized by indicated color and stratified by S-IgG (BAU/ml)
729 for BQ.1.1 variant. Dotted line represents 50% of all participants in each stratum. N of
730 each stratum is indicated on top of the graph.

731 (e) Spearman correlations of Wu01 ID₅₀ against BA.4/5 ID₅₀ (left), Wu01 ID₅₀ against
732 BQ.1.1 ID₅₀ (middle) and BA.4/5 ID₅₀ against BQ.1.1 ID₅₀ (right). Blue lines indicate fit
733 lines computed with robust regression

734 (f) Stepwise forward regression models for predicting BQ.1.1 serum neutralization
735 (ID₅₀) using continuous features (age, height, weight, body mass index (BMI), number
736 of infections, number of vaccinations, time since infection, time since vaccination, S-
737 IgG) and categorical features (sex, pre-conditions, NC-IgG and immunosuppression).
738 Features with $p < 0.05$ in the multivariable regression model are highlighted in red.

739 (g) Bayesian networks of the features predicting BQ.1.1 serum neutralization (ID₅₀).
740 The graph connects the features, which are predictive of each other with serum
741 neutralization as sink. Features with $p < 0.05$ in the multivariable regression model (F)
742 are highlighted in red.

743

Figure 1




Figure 2






Figure 3

a


Serum neutralization



b



c



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Figure 4










Figure 5



Supplementary information

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients

Supplementary Figure 1	Recruitment of emergency room patients
Supplementary Figure 2	CONSORT flow diagram
Supplementary Figure 3	SARS-CoV-2 antibody prevalence in emergency department patients (additional features)
Supplementary Figure 4	Sub-sampling for determination of BQ1.1 serum neutralization (Age and sex)
Supplementary Figure 5	Sub-sampling for determination of BQ1.1 serum neutralization (S-IgG and ID ₅₀)
Supplementary Table 1	Study demographics, clinical information, and SARS-CoV-2 immune status




Supplementary Figure 1: Recruitment of emergency department patients


(a) Illustration depicting eligibility criteria for participation.

(b) Pie charts illustrating sex distribution of study population and sample. Sex of 1 patient and 3 participants was not available. Two-sided Fisher's exact test ($p=0.231$) was performed for statistical analyses.

(c) Dot plot illustrating age distribution of study population and sample. Age of 5 participants was not available. Median age is indicated by horizontal line, standard deviation is indicated by error bars. Mann-Whitney test was performed for statistical analyses. Ns indicates a p -value < 0.05 .




Supplementary Figure 2: CONSORT flow diagram



Supplementary Figure 3: SARS-CoV-2 antibody prevalence in emergency room patients (additional features)


Dot plots depicting S-IgG BAU/ml values, subdivided based on number of reported vaccinations, number of reported infections, and NC-IgG detection. Dotted lines represent the limit of detection (33.8 BAU/ml). Geometric means are indicated by horizontal red lines and listed in each plot over total fractions of participants with detectable Spike IgG. Two-sided Kruskal-Wallis-tests and Dunn's multiple comparisons tests were performed for statistical analyses. Ns, *, **, ***, and **** represent p-values ≥ 0.05 , < 0.05 , ≤ 0.01 , ≤ 0.001 , and ≤ 0.0001 , respectively.



Supplementary Figure 4: Sub-sampling for determination of BQ1.1 serum neutralization (Age and sex)

(a) Illustration depicting statistical procedure for sub-sampling. Proportionate stratified random sampling was conducted to draw a representative sub-sample (n=423).

(b) Dot plots depicting age distributions of all enrolled participants (BESU study sample) and the sub-sample, subdivided by sex and age-strata. Median ages are indicated by horizontal red lines and given above the dots. Two-sided Mann-Whitney tests and Kruskal-Wallis tests were performed for statistical analyses. Ns represents p-values > 0.05.



Supplementary Figure 5: Sub-sampling for determination of BQ1.1 serum neutralization (S-IgG and ID₅₀)

Dot plots depicting S-IgG values (BAU/ml) and serum neutralization (ID₅₀) of the entire study population and the sub-sample stratified by sex. Geometric means are indicated by horizontal red lines and given above the dots. Two-sided Mann-Whitney tests and Kruskal-Wallis tests were performed for statistical analyses. Ns represents p-values > 0.05.

Supplementary Table 1: Study demographics, clinical information, and SARS-CoV-2 immune status

Gender	Male		Female		Unknown	
	(n)	(%)	(n)	(%)	(n)	(%)
	684	48,48	724	51,31	3	0,21

Age	Median	Range
	(years)	(years)
	53	18-89

Pre-conditions	No		Yes		Unknown	
	(n)	(%)	(n)	(%)	(n)	(%)
	482	34,16	906	64,21	23	1,63

Drug immunosuppression	No		Yes		Unknown	
	(n)	(%)	(n)	(%)	(n)	(%)
	1186	84,05	192	13,61	33	2,34

COVID-19 vaccination	Vaccination status	(n)	(%)	Time since last vaccination	
				Median	Range
				(months)	(months)
	No vaccination	74	5,24	NA	NA
	1 vaccination	32	2,27	11,17	6,1-19,7
	2 vaccinations	197	13,96	10,9	1,5-28,4
	3 vaccinations	766	54,29	8,733	0-20
	4 vaccinations	331	23,46	4,933	0-19,7
	>4 vaccinations	6	0,43	5,7	1,7-10,6
	Unknown	5	0,35	NA	NA

SARS-CoV-2 infections	Infection status	(n)	(%)	Time since last infection	
				Median	Range
				(months)	(months)
	No infection	766	54,29	NA	NA
	1 infection	579	41,03	5,30	0-32,6
	2 infections	55	3,90	4,40	0,4-19,3
	3 infections	5	0,35	5,60	2,9-7,4
	Unknown	6	0,43	NA	NA

NA= Not applicable